Corrie P, Terheyden P, ten Tije AJ, et al. A prospective observational safety study of patients (pts) with BRAFV600E-mutated unresectable or metastatic melanoma (MM) treated with vemurafenib (VEM) (Zelboraf Safety Study [ZeSS]): final results. SMR 2017, abstract P17-7.
Fysieke inactiviteit de grootste modificeerbare risicofactor in de geneeskunde
nov 2023 | Bewegingsstoornissen, Dementie, Diabetes, Epilepsie, Hoofdpijn, Multipele Sclerose, Neuro-musculair, Neuro-vasculair